The effect of simvastatin on the serum monocyte chemoattractant protein-1 and intracellular adhesion molecule-1 levels in diabetic rats

Journal of Diabetes and its Complications

Volumn 23, Issue 3, 2009, Pages 214-218

  Lin, Yang ^a   Ye, Shandong ^a   Chen, Yan ^a   Li, Xiucai ^a   Yang, Guang wei ^a   Fan, Aihong ^a   Wang, Yingxin ^b  

^a ANHUI PROVINCIAL HOSPITAL   (China)

^b Anhui Medical College   (China)

Author keywords

Diabetes mellitus; ICAM 1; Macroangiopathy; MCP 1; Simvastatin

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; SIMVASTATIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; TREATMENT DURATION; TREATMENT OUTCOME; WISTAR RAT;

ANIMALS; CHEMOKINE CCL2; DIABETES MELLITUS, EXPERIMENTAL; INTERCELLULAR ADHESION MOLECULE-1; MALE; RATS; RATS, WISTAR; SIMVASTATIN;

EID: 65249124085     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2007.09.003     Document Type: Article

References (20)

1. Carlos T.M., and Harlan J.M. Leukocyte-endothelial adhesion molecules. Blood 84 (1994) 2068-2102
2. Ceriello A., Quagliaro L., Piconi L., Assaloni R., Ros R.D., Maier A., Esposito K., and Giugliano D. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin in treatment. Diabetes 53 (2004) 701-710
3. DeGraba T.J., Siren A.L., Penix L., McCarron R.M., Hargraves R., Sood S., Karen D., Pettigrew K.D., and Hallenbeck J.M. Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque. Stroke 29 (1998) 1405-1410
4. De Lemos J.A., Morrow D.A., Sabatine M.S., Murphy S.A., Gibson C.M., Antman E.M., McCabe C.H., Cannon C.P., and Braunwald E. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 107 (2003) 690-695
5. Dichtl W., Dulak J., Frick M., Alber H.F., Schwarzacher S.P., Ares M.P., Nilsson J., Pachinger O., and Weidinger F. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular 23 (2003) 58-63
6. Ehlermann P., Eggers K., Bierhaus A., Most P., Weichenhan D., Greten J., Nawroth P.P., Katus H.A., and Remppis A. Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovascular Diabetologica 5 (2006) 1-9
7. Han K.H., Ryu J., Hong K.H., Ko J., Pak Y.K., Kim J.B., Park S.W., and Kim J.J. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation 111 (2005) 1439-1447
8. Jang Y., Lincoff A.M., Plow E.F., and Topol E.J. Cell adhesion molecules in coronary artery disease. Journal of the American College of Cardiology 24 (1994) 1591-1601
9. Kleemann R., Verschuren L., de Rooij B.J., Lindeman J., de Maat M.M., Szalai A.J., Princen H.M., and Kooistra T. Evidence for anti-inflammatory activity of statins and PPAR-α activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 103 (2004) 4188-4194
10. Koh K.K., Quon M.J., Han S.H., Chung W.J., Ahn J.Y., Seo Y.H., Kang M.H., Ahn T.H., Choi I.S., and Shin E.K. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110 (2004) 3687-3692
11. Lee S., Kim B., Sik Y., Kim S.B., Park S.K., and Park J.S. High glucose induces MCP-1 expression partly via tyrosine kinase-AP-1 pathway in peritoneal mesothelial cells. Kidney International 60 (2001) 55-64
12. Li D., Chen H., Romeo F., Sawamura T., Saldeen T., and Mehta J.L. Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: Role of LOX-1. Pharmacology & Therapeutics 302 (2002) 601-605
13. März W., and Köenig W. HMG-CoA reductase inhibition: Anti-inflammatory effects beyond lipid lowering?. Journal of Cardiovascular Risk 10 (2003) 169-179
14. Nomura S., Shouzu A., Omoto S., Nishikawa M., and Fukuhara S. Significance of chemokines and activated platelets in patients with diabetes. Clinical and Experimental Immunology 121 (2000) 437-443
15. Romano M., Diomede L., Sironi M., Massimiliano L., Sottocorno M., Polentarutti N., Guqlielmotti A., Albani D., Bruno A., Fruscella P., Salmona M., Vecchi A., Pinza M., and Mantovani A. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Laboratory Investigation 80 (2000) 1095-1100
16. Sowers J.R. Effects of statins on the vasculature: Implications for aggressive lipid management in the cardiovascular metabolic syndrome. American Journal of Cardiology 91 (2003) 14B-22B
17. Takemoto M., Node K., Nakagami H., Liao Y., Grimm M., Takemoto Y., Kitakaze M., and Liao J.K. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. Journal of Clinical Investigation 108 (2001) 1429-1437
18. Wierzbicki A.S., Poston R., and Ferro A. The lipid and non-lipid effects of statins. Pharmacology & Therapeutics 99 (2003) 95-112
19. Zhan Y., Brown C., Maynard E., Anshelevich A., Ni W., Ho I.C., and Oettgen P. Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. Journal of Clinical Investigation 115 (2005) 2508-2516
20. Zhu D.L. The relationship between inflammation and type 2 diabetes. Chinese Journal of Investigative 14 (2006) 73-74